Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance
Camilla Jandus, … , Christian Münz, Stephan von Gunten
Camilla Jandus, … , Christian Münz, Stephan von Gunten
Published February 24, 2014
Citation Information: J Clin Invest. 2014;124(4):1810-1820. https://doi.org/10.1172/JCI65899.
View: Text | PDF
Research Article Immunology Article has an altmetric score of 29

Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance

  • Text
  • PDF
Abstract

Alteration of the surface glycosylation pattern on malignant cells potentially affects tumor immunity by directly influencing interactions with glycan-binding proteins (lectins) on the surface of immunomodulatory cells. The sialic acid–binding Ig-like lectins Siglec-7 and -9 are MHC class I–independent inhibitory receptors on human NK cells that recognize sialic acid–containing carbohydrates. Here, we found that the presence of Siglec-9 defined a subset of cytotoxic NK cells with a mature phenotype and enhanced chemotactic potential. Interestingly, this Siglec-9+ NK cell population was reduced in the peripheral blood of cancer patients. Broad analysis of primary tumor samples revealed that ligands of Siglec-7 and -9 were expressed on human cancer cells of different histological types. Expression of Siglec-7 and -9 ligands was associated with susceptibility of NK cell–sensitive tumor cells and, unexpectedly, of presumably NK cell–resistant tumor cells to NK cell–mediated cytotoxicity. Together, these observations have direct implications for NK cell–based therapies and highlight the requirement to consider both MHC class I haplotype and tumor-specific glycosylation.

Authors

Camilla Jandus, Kayluz Frias Boligan, Obinna Chijioke, He Liu, Meike Dahlhaus, Thomas Démoulins, Christoph Schneider, Marc Wehrli, Robert E. Hunger, Gabriela M. Baerlocher, Hans-Uwe Simon, Pedro Romero, Christian Münz, Stephan von Gunten

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2009 Total
Citations: 8 33 22 27 41 34 16 13 7 18 7 5 1 232
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (232)

Title and authors Publication Year
Proximity Labeling and Genetic Screening Reveal that DSG2 is a Counter Receptor of Siglec‐9 and Suppresses Macrophage Phagocytosis
Wu Y, You Y, Jiang T, He Y, Fan Q, Zeng X, Li T, Lu Y, Qi L, Zhou F, Sun L, Wang D, Zou Y, Zhang G, Yuan Y, Mao Y
Advanced Science 2025
HIV-Induced Sialoglycans on Infected Cells Promote Immune Evasion from Myeloid Cell-Mediated Killing
Singh S, Islam SM, Liu R, Adeniji OS, Giron LB, Saini P, Danesh A, Denton PW, Jones B, Xiao H, Abdel-Mohsen M
bioRxiv 2025
Insights on the Role of Sialic Acids in Acute Lymphoblastic Leukemia in Children
Radu KR, Baek KH
International Journal of Molecular Sciences 2025
Tumor Glycosylation: A Main Player in the Modulation of Immune Responses
Rodriguez E
European Journal of Immunology 2025
Natural killer cells: the immune frontline against circulating tumor cells
Masmoudi D, Villalba M, Alix-Panabières C
Journal of Experimental & Clinical Cancer Research : CR 2025
Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay
Nikseresht S, Shewell LK, Day CJ, Jennings MP, Chittoory H, McCart Reed AE, Simpson PT, Lakhani SR, Nabiee R, Moore M, Khanabdali R, Hinch LM, Rice GE
Breast Cancer Research and Treatment 2025
The Epithelial Immune Response to Human Papillomavirus Infection
Roy-Biswas S, Hibma M
Pathogens 2025
Potentiating T cell tumor targeting using a combination of TCR with a Siglec-7 based CSR
Didi-Zurinam S, Katzman E, Cohen CJ
Frontiers in Immunology 2025
The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy
Feng H, Feng J, Han X, Ying Y, Lou W, Liu L, Zhang L
Cancers 2024
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective
Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, Grishanina NR, Kwok D, Stevers NO, Jin Q, Youngblood MW, Stasiak LA, Hou Y, Wang J, Yamaguchi TN, Lafontaine M, Shai A, Smirnov IV, Solomon DA, Chang SM, Hervey-Jumper SL, Berger MS, Lupo JM, Okada H, Phillips JJ, Boutros PC, Gallo M, Oldham MC, Yue F, Costello JF
Cell 2024
The transcriptional landscape of glycosylation-related genes in cancer
Rodriguez E, Lindijer DV, van Vliet SJ, Garcia Vallejo JJ, van Kooyk Y
iScience 2024
Unraveling the impact of a glyco-immune checkpoint in bone metastasis
Läubli H
Proceedings of the National Academy of Sciences 2024
Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R, Sandholzer M, Carlini E, Lin CW, Börsch A, Zingg A, Lardinois D, Herzig P, Don L, Zippelius A, Läubli H, Mantuano NR
Cellular & molecular immunology 2024
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.
Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt EN, Walker L, Adamson B, Buskin A, Hepburn AC, Hodgson K, Kendall H, Frame FM, Maitland N, Coffey K, Strand DW, Robson CN, Elliott DJ, Heer R, Macauley M, Munkley J, Gaughan L, Leslie J, Scott E
Communications biology 2024
Dissecting the Ability of Siglecs To Antagonize Fcγ Receptors
McCord KA, Wang C, Anhalt M, Poon WW, Gavin AL, Wu P, Macauley MS
ACS Central Science 2024
GD2-targeting therapy: a comparative analysis of approaches and promising directions
Philippova J, Shevchenko J, Sennikov S
Frontiers in immunology 2024
Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.
Ayyalasomayajula R, Cudic M
Cancers 2024
Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions.
Boelaars K, Rodriguez E, Huinen ZR, Liu C, Wang D, Springer BO, Olesek K, Goossens-Kruijssen L, van Ee T, Lindijer D, Tak W, de Haas A, Wehry L, Nugteren-Boogaard JP, Mikula A, de Winde CM, Mebius RE, Tuveson DA, Giovannetti E, Bijlsma MF, Wuhrer M, van Vliet SJ, van Kooyk Y
Communications biology 2024
Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.
Ren X, Lin S, Guan F, Kang H
International journal of biological sciences 2024
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.
Mitra A, Kumar A, Amdare NP, Pathak R
Biology 2024
Limited impact of cancer-derived gangliosides on anti-tumor immunity in colorectal cancer
van der Haar Àvila I, Zhang T, Lorrain V, de Bruin F, Spreij T, Nakayama H, Iwabuchi K, García-Vallejo JJ, Wuhrer M, van Kooyk Y, van Vliet SJ
Glycobiology 2024
Uncloaking the viral glycocalyx: How do viruses exploit glycoimmune checkpoints?
Domma AJ, Henderson LA, Nurdin JA, Kamil JP
Advances in virus research 2024
Anticancer approach by targeted activation of a global inhibitor of sialyltransferases with acrolein
Kasahara T, Chang TC, Yoshioka H, Urano S, Egawa Y, Inoue M, Tahara T, Morimoto K, Pradipta AR, Tanaka K
Chemical Science 2024
Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review
Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N
Frontiers in Oncology 2024
Fusobacterium nucleatum subsp. nucleatum RadD binds Siglec-7 and inhibits NK cell-mediated cancer cell killing
Galaski J, Rishiq A, Liu M, Bsoul R, Bergson A, Lux R, Bachrach G, Mandelboim O
iScience 2024
Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications.
Liu J, Xu X, Zhong H, Yu M, Abuduaini N, Zhang S, Yang X, Feng B
Biomedicines 2024
Siglec‐7 and Siglec‐9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling
van Houtum EJ, Valk AH, Granado D, Lok J, van den Bogaard L, Remkes N, van Eck van der Sluijs J, Span PN, Cornelissen LA, Adema GJ
Clinical & Translational Immunology 2024
Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy
Wang C, He L, Peng J, Lu C, Zhang M, Qi X, Zhang M, Wang Y
Journal for Immunotherapy of Cancer 2024
The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.
Barzegari A, Salemi F, Kamyab A, Aratikatla A, Nejati N, Valizade M, Eltouny E, Ebrahimi A
Journal of bone oncology 2024
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer
Ru Wen, Jessica C Stark, G. Edward W. Marti, Zenghua Fan, Aram Lyu, Fernando Garcia-Marques, Xiangyue Zhang, Nicholas M. Riley, Sarah M Totten, Abel Bermudez, Rosalie Nolley, Hongjuan Zhao, Lawrence Fong, Edgar Engleman, Sharon J Pitteri, Carolyn R. Bertozzi, James D. Brooks
Journal of Clinical Investigation 2024
Measuring carbohydrate recognition profile of lectins on live cells using liquid glycan array (LiGA).
Sojitra M, Schmidt EN, Lima GM, Carpenter EJ, McCord KA, Atrazhev A, Macauley MS, Derda R
Nature protocols 2024
Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects
Wolters-Eisfeld G, Oliveira-Ferrer L
Seminars in Immunopathology 2024
Reshaping the tumor microenvironment by degrading glycoimmune checkpoints Siglec-7 and -9.
Wang C, Hou Y, Zak J, Zheng Q, McCord KA, Wu M, Zhang D, Chung S, Shi Y, Ye J, Zhao Y, Hajjar S, Wilson IA, Paulson JC, Teijaro JR, Zhou X, Sharpless KB, Macauley MS, Wu P
bioRxiv : the preprint server for biology 2024
A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer.
Ma X, Wei X, Yang G, Li S, Liu R
Combinatorial chemistry & high throughput screening 2024
Modifying the Glycocalyx of Melanoma Cells via Metabolic Glycoengineering Using N-Acetyl-d-glucosamine Analogues
Harris D, Groß M, Staebler S, Ebert R, Seibel J, Boßerhoff AK
Cells 2024
Effect of Hypoxia on Siglec-7 and Siglec-9 Receptors and Sialoglycan Ligands and Impact of Their Targeting on NK Cell Cytotoxicity
Nawafleh H, Zeinelabdin N, Greene MK, Krishnan A, Ho L, Genead M, Kunimoto D, Scott CJ, Tolentino M, Chouaib S
Pharmaceuticals 2024
Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes
Lustig M, Hahn C, Leangen Herigstad M, Andersen JT, Leusen JH, Burger R, Valerius T
Frontiers in Oncology 2024
Siglec‐G Suppresses CD8+ T Cells Responses through Metabolic Rewiring and Can be Targeted to Enhance Tumor Immunotherapy
Yin S, Li C, Shen X, Yu G, Cui L, Wu Y, He Y, Yu S, Chen J, Lu S, Qiu G, Song M, Qian C, Zou Z, Yu Y, Xu S
Advanced Science 2024
Alcohol induces α2‐6sialo mucin O‐glycans that kill U937 macrophages mediated by sialic acid‐binding immunoglobulin‐like lectin 7 (Siglec 7)
Cheng P, Hothpet V, Bhat G, Bailey K, Li L, Samuelson DR
FEBS Open Bio 2024
Unveiling sialoglycans’ immune mastery in pregnancy and their intersection with tumor biology
Huang J, Feng L, Huang J, Zhang G, Liao S
Frontiers in Immunology 2024
Harnessing the biology of regulatory T cells to treat disease.
Wardell CM, Boardman DA, Levings MK
Nature reviews. Drug discovery 2024
RNA therapeutics for improving CAR T cell safety and efficacy
Schaible P, Bethge W, Lengerke C, Haraszti RA
Cancer research 2023
Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
Saini P, Adeniji OS, Bordoloi D, Kinslow J, Martinson J, Parent DM, Hong KY, Koshy J, Kulkarni AJ, Zilberstein NF, Balk RA, Moy JN, Giron LB, Tracy RP, Keshavarzian A, Muthumani K, Landay A, Weiner DB, Abdel-Mohsen M
mBio 2023
The Blessed Union of Glycobiology and Immunology: A Marriage That Worked.
Dos Reis JS, Diniz-Lima I, Santos MARDC, Barcelos PM, da Costa KM, Valente RDC, Chaves LS, de Campos LP, Dos Santos AC, Correia de Lima RG, Decote-Ricardo D, Morrot A, Previato JO, Mendonça-Previato L, Freire-de-Lima CG, Fonseca LMD, Freire-de-Lima L
2023
Diversity of immune checkpoints in cancer immunotherapy
Guo Z, Zhang R, Yang AG, Zheng G
Frontiers in immunology 2023
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
Smith BA, Deutzmann A, Correa KM, Delaveris CS, Dhanasekaran R, Dove CG, Sullivan DK, Wisnovsky S, Stark JC, Pluvinage JV, Swaminathan S, Riley NM, Rajan A, Majeti R, Felsher DW, Bertozzi CR
Proceedings of the National Academy of Sciences 2023
Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics
Čaval T, Alisson-Silva F, Schwarz F
Theranostics 2023
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
Raza A, Mohsen R, Kanbour A, Zar Gul AR, Philip A, Vijayakumar S, Hydrose S, Prabhu KS, Al-Suwaidi AK, Inchakalody VP, Merhi M, Abo El-Ella DM, Tauro MA, Akbar S, Al-Bozom I, Abualainin W, Al-Abdulla R, Sirriya SA, Hassnad S, Uddin S, Mohamed Ibrahim MI, Al Homsi U, Demime S
Frontiers in immunology 2023
Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH, Kers-Rebel ED, Looman MW, Hooijberg E, Büll C, Granado D, Cornelissen LAM, Adema GJ
Cellular and molecular life sciences : CMLS 2023
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
Lustig M, Chan C, Jansen JH, Bräutigam M, Kölling MA, Gehlert CL, Baumann N, Mester S, Foss S, Andersen JT, Bastian L, Sondermann P, Peipp M, Burger R, Leusen JH, Valerius T
Frontiers in immunology 2023
Sialylation: A Cloak for Tumors to Trick the Immune System in the Microenvironment
Zhou X, Chi K, Zhang C, Liu Q, Yang G
Biology 2023
Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity
Zheng P, Dou Y, Wang Q
Frontiers in Cellular and Infection Microbiology 2023
Role of Truncated O-GalNAc Glycans in Cancer Progression and Metastasis in Endocrine Cancers
Pinto D, Parameswaran R
Cancers 2023
Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9
Chan C, Lustig M, Jansen JH, Garcia Villagrasa L, Raymakers L, Daamen LA, Valerius T, van Tetering G, Leusen JH
Cancers 2023
T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems
Yang YL, Yang F, Huang ZQ, Li YY, Shi HY, Sun Q, Ma Y, Wang Y, Zhang Y, Yang S, Zhao GR, Xu FH
Frontiers in immunology 2023
Structural and molecular insight into antibody recognition of dynamic neoepitopes in membrane tethered MUC1 of pancreatic cancer cells and secreted exosomes
Wakui H, Yokoi Y, Horidome C, Ose T, Yao M, Tanaka Y, Hinou H, Nishimura SI
2023
Siglec-9+ tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
Wang Y, He M, Zhang C, Cao K, Zhang G, Yang M, Huang Y, Jiang W, Liu H
Journal for ImmunoTherapy of Cancer 2023
Siglec-9 is an inhibitory receptor on human mast cells in vitro
Miralda I, Samanas NB, Seo AJ, Foronda JS, Sachen J, Hui Y, Morrison SD, Oskeritzian CA, Piliponsky AM
Journal of Allergy and Clinical Immunology 2023
Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers
Bordoloi D, Kulkarni AJ, Adeniji OS, Pampena MB, Bhojnagarwala PS, Zhao S, Ionescu C, Perales-Puchalt A, Parzych EM, Zhu X, Ali AR, Cassel J, Zhang R, Betts MR, Abdel-Mohsen M, Weiner DB
Science Advances 2023
Genome Editing in Engineered T Cells for Cancer Immunotherapy
Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani CF, Qasim W
Human Gene Therapy 2023
Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
Boelaars K, Goossens-Kruijssen L, Wang D, de Winde CM, Rodriguez E, Lindijer D, Springer B, van der Haar Àvila I, de Haas A, Wehry L, Boon L, Mebius RE, van Montfoort N, Wuhrer M, den Haan JM, van Vliet SJ, van Kooyk Y
Journal for ImmunoTherapy of Cancer 2023
Triply Enhanced Immunotherapy via Dual Glycan Reforming Integrated with Perforation.
Yang Y, Wang Y, Chao Z, Yang Y, Fang Y, Liu Y, Ding L, Chen Y, Ju H
2023
The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.
Stewart N, Daly J, Drummond-Guy O, Krishnamoorthy V, Stark JC, Riley NM, Williams KC, Bertozzi CR, Wisnovsky S
The Journal of biological chemistry 2023
Molecular Basis and Role of Siglec-7 Ligand Expression on Chronic Lymphocytic Leukemia B Cells
L Chang, S Liang, S Lu, H Tseng, H Tsai, C Tang, M Sugata, Y Chen, Y Chen, S Wu, K Lin, K Khoo, T Angata
Frontiers in immunology 2022
Sweet Immune Checkpoint Targets to Enhance T Cell Therapy
N Derosiers, W Aguilar, D DeGaramo, A Posey
Journal of immunology (Baltimore, Md. : 1950) 2022
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
A Archilla-Ortega, C Domuro, J Martin-Liberal, P Muñoz
Journal of Experimental & Clinical Cancer Research 2022
Engineered NK Cells Against Cancer and Their Potential Applications Beyond
M Karvouni, M Vidal-Manrique, A Lundqvist, E Alici
Frontiers in immunology 2022
Unconventional protein post-translational modifications: the helmsmen in breast cancer
J Liu, Q Wang, Y Kang, S Xu, D Pang
Cell & Bioscience 2022
Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer
J Wang, M Manni, A Bärenwaldt, R Wieboldt, N Kirchhammer, R Ivanek, M Stanczak, A Zippelius, D König, N Manutano, H Läubli
Frontiers in Cell and Developmental Biology 2022
Immunosuppressive glycoproteins associate with breast tumor fibrosis and aggression
K Metcalf, M Hayward, E Berens, A Ironside, C Stashko, E Hwang, V Weaver
2022
Tumor suppression via diverting intracellular sialylation with multifunctional nanoparticles
Y Chen, Y Yang, Q Tan, H Liu, H Ju
Chemical Science 2022
The intriguing roles of Siglec family members in the tumor microenvironment
K Jiang, L Qi, F Kang, L Wang
Biomarker Research 2022
Increased expression of TIGIT and KLRG1 correlates with impaired CD56bright NK cell immunity in HPV16-related cervical intraepithelial neoplasia
Y Nie, D Liu, W Yang, Y Li, L Zhang, X Cheng, R Chen, B Yuan, G Zhang, H Wang
Virology Journal 2022
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
Daly J, Sarkar S, Natoni A, Stark JC, Riley NM, Bertozzi CR, Carlsten M, O'Dwyer ME
Blood Advances 2022
Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?
Chan C, Lustig M, Baumann N, Valerius T, van Tetering G, Leusen JH
Frontiers in immunology 2022
Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
Talaat IM, Elemam NM, Zaher S, Saber-Ayad M
Frontiers in Medicine 2022
Aberrant Sialylation in Cancer: Therapeutic Opportunities.
Munkley J
Cancers 2022
The new progress in cancer immunotherapy.
Shimu AS, Wei HX, Li Q, Zheng X, Li B
Clinical and Experimental Medicine 2022
Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities
Haas Q, Markov N, Muerner L, Rubino V, Benjak A, Haubitz M, Baerlocher GM, Ng CK, Münz C, Riether C, Ochsenbein AF, Simon HU, von Gunten S
Frontiers in immunology 2022
Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.
Huang J, Li M, Mei B, Li J, Zhu Y, Guo Q, Huang J, Zhang G
Journal of Translational Medicine 2022
Inhibitory Siglec-sialic acid interactions in balancing immunological activation and tolerance during viral infections
Saini P, Adeniji OS, Abdel-Mohsen M
EBioMedicine 2022
Development of Effective Siglec-9 Antibodies Against Cancer
Wang JH, Jiang N, Jain A, Lim J
Current Oncology Reports 2022
Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity
Huang J, Huang J, Zhang G
Cancers 2022
Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy
Makandar AI, Jain M, Yuba E, Sethi G, Gupta RK
Human vaccines 2022
Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.
Läubli H, Nalle SC, Maslyar D
Cancer immunology research 2022
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, Sanin DE, Jacob F, Coelho R, Everest-Dass AV, Wang J, Trefny MP, Monaco G, Bärenwaldt A, Gray MA, Petrone A, Kashyap AS, Glatz K, Kasenda B, Normington K, Broderick J, Peng L, Pearce OMT, Pearce EL, Bertozzi CR, Zippelius A, Läubli H
Science Translational Medicine 2022
Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec‐7
Fan T, Liao Q, Zhao Y, Dai H, Song S, He T, Wang Z, Huang J, Zeng Z, Guo H, Zhang H, Qiu X
Cancer Science 2022
Directing CAR NK Cells via the Metabolic Incorporation of CAR Ligands into Malignant Cell Glycans
Antillon K, Ross PA, Farrell MP
ACS chemical biology 2022
Glycan targeting nanoparticle for photodynamic immunotherapy of melanoma
Choi Y, Son W, Han Y, Chae J, Yang CS, Choi J
Acta pharmaceutica Sinica. B 2022
The multifaceted role of MUC1 in tumor therapy resistance.
Jin W, Zhang M, Dong C, Huang L, Luo Q
Clinical and Experimental Medicine 2022
Leveraging Microenvironmental Synthetic Lethalities to Treat Cancer
Kevin Metcalf, Alaa Alazzeh, Zena Werb, Valerie Weaver
Journal of Clinical Investigation 2021
Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells
OS Adeniji, L Kuri-Cervantes, C Yu, Z Xu, M Ho, GM Chew, C Shikuma, C Tomescu, AF George, NR Roan, LC Ndhlovu, Q Liu, K Muthumani, DB Weiner, MR Betts, H Xiao, M Abdel-Mohsen, F Margottin-Goguet
PLoS pathogens 2021
Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity
I Ibarlucea-Benitez, P Weitzenfeld, P Smith, JV Ravetch
Proceedings of the National Academy of Sciences 2021
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
DM Bedoya, V Dutoit, D Migliorini
Frontiers in immunology 2021
Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment
NM Kaweme, F Zhou
Frontiers in immunology 2021
Re-Expression of Poly/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape
M Jarahian, F Marofi, MS Maashi, M Ghaebi, A Khezri, MR Berger
Cancers 2021
Probing the binding specificities of human Siglecs by cell-based glycan arrays
C Büll, R Nason, L Sun, JV Coillie, DM Sørensen, SJ Moons, Z Yang, S Arbitman, SM Fernandes, S Furukawa, R McBride, CM Nycholat, GJ Adema, JC Paulson, RL Schnaar, TJ Boltje, H Clausen, Y Narimatsu
Proceedings of the National Academy of Sciences 2021
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model
P Wielgat, N Wawrusiewicz-Kurylonek, R Czarnomysy, K Rogowski, K Bielawski, H Car
International journal of molecular sciences 2021
The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology
M Hugonnet, P Singh, Q Haas, S von Gunten
Frontiers in immunology 2021
Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry
B Shibru, K Fey, S Fricke, AR Blaudszun, F Fürst, M Weise, S Seiffert, MK Weyh, U Köhl, U Sack, A Boldt
Frontiers in immunology 2021
Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
N Jacquelot, C Seillet, F Souza-Fonseca-Guimaraes, AG Sacher, GT Belz, PS Ohashi
International journal of molecular sciences 2021
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
I Buckle, C Guillerey
Cancers 2021
Regulation of prognosis-related Siglecs in the glioma microenvironment
R Mao, L Zhou, Y Yang, P Wang, H Lin, J Zheng, G Lv, D Zhou
Journal of Cancer Research and Clinical Oncology 2021
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
BA Smith, CR Bertozzi
Nature Reviews Drug Discovery 2021
Small RNAs are modified with N-glycans and displayed on the surface of living cells
RA Flynn, K Pedram, SA Malaker, PJ Batista, BA Smith, AG Johnson, BM George, K Majzoub, PW Villalta, JE Carette, CR Bertozzi
Cell 2021
Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells
A Yoshimura, Y Asahina, LY Chang, T Angata, H Tanaka, K Kitajima, C Sato
The Journal of biological chemistry 2021
Research progress on O-GlcNAcylation in the occurrence, development, and treatment of colorectal cancer
Y Liu, FX Peng
World journal of gastrointestinal surgery 2021
Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages
A Poggi, F Villa, JL Fernadez, D Costa, MR Zocchi, R Benelli
Cancers 2021
Combined Effect of Anti-SSEA4 and Anti-Globo H Antibodies on Breast Cancer Cells
RH Lee, YJ Wang, TY Lai, TL Hsu, PK Chuang, HC Wu, CH Wong
ACS chemical biology 2021
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
Y Xu, Z Gao, R Hu, Y Wang, Y Wang, Z Su, X Zhang, J Yang, M Mei, Y Ren, M Li, X Zhou
Journal for ImmunoTherapy of Cancer 2021
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
S Wisnovsky, L Möckl, SA Malaker, K Pedram, GT Hess, NM Riley, MA Gray, BA Smith, MC Bassik, WE Moerner, CR Bertozzi
Proceedings of the National Academy of Sciences 2021
Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity cis -Ligands
S Hong, C Yu, E Rodrigues, Y Shi, H Chen, P Wang, DG Chapla, T Gao, R Zhuang, KW Moremen, JC Paulson, MS Macauley, P Wu
ACS Central Science 2021
Ganglioside GD3 May Suppress the Functional Activities of Benign Skin T Cells in Cutaneous T-Cell Lymphoma
M Kume, E Kiyohara, Y Matsumura, H Koguchi-Yoshioka, A Tanemura, Y Hanaoka, M Taminato, H Tashima, K Tomita, T Kubo, R Watanabe, M Fujimoto
Frontiers in immunology 2021
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
N Xiao, X Zhu, K Li, Y Chen, X Liu, B Xu, M Lei, J Xu, HC Sun
Experimental Hematology and Oncology 2021
Modulation of immune cell reactivity with cis -binding Siglec agonists
CS Delaveris, SH Chiu, NM Riley, CR Bertozzi
Proceedings of the National Academy of Sciences 2021
Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments
E Gianchecchi, A Arena, A Fierabracci
International journal of molecular sciences 2021
Glycosylation of Cancer Extracellular Vesicles: Capture Strategies, Functional Roles and Potential Clinical Applications
ÁM Martins, CC Ramos, D Freitas, CA Reis
Cells 2021
Increased Frequency of Dysfunctional Siglec-7−CD57+PD-1+ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease
Y Sakamoto, S Yoshio, H Doi, T Mori, M Matsuda, H Kawai, T Shimagaki, S Yoshikawa, Y Aoki, Y Osawa, Y Yoshida, T Arai, N Itokawa, M Atsukawa, T Ito, T Honda, Y Mise, Y Ono, Y Takahashi, A Saiura, A Taketomi, T Kanto
Frontiers in immunology 2021
Phenotypic Characterization by Single-Cell Mass Cytometry of Human Intrahepatic and Peripheral NK Cells in Patients with Hepatocellular Carcinoma
Y Yoshida, S Yoshio, T Yamazoe, T Mori, Y Tsustui, H Kawai, S Yoshikawa, T Fukuhara, T Okamoto, Y Ono, Y Takahashi, R Hashida, T Kawaguchi, A Taketomi, T Kanto
Cells 2021
Sialic Acids and Their Influence on Human NK Cell Function
P Rosenstock, T Kaufmann
Cells 2021
5-AZA-dC induces epigenetic changes associated with modified glycosylation of secreted glycoproteins and increased EMT and migration in chemo-sensitive cancer cells
G Greville, E Llop, J Howard, SF Madden, AS Perry, R Peracaula, PM Rudd, A McCann, R Saldova
Clinical Epigenetics 2021
Metabolic Glycoengineering in hMSC-TERT as a Model for Skeletal Precursors by Using Modified Azide/Alkyne Monosaccharides
S Altmann, J Mut, N Wolf, J Meißner-Weigl, M Rudert, F Jakob, M Gutmann, T Lühmann, J Seibel, R Ebert
International journal of molecular sciences 2021
Siglecs as Therapeutic Targets in Cancer
J Lim, D Sari-Ak, T Bagga
Biology : open access journal 2021
[Universal chimeric antigen receptor T cells therapy: current status and future perspectives]
Y Huang, K J Hu, Y X Hu, H Huang
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2021
Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity
H Choi, M Ho, OS Adeniji, L Giron, D Bordoloi, AJ Kulkarni, AP Puchalt, M Abdel-Mohsen, K Muthumani
Frontiers in Oncology 2021
Inhibitory pattern recognition receptors
M Rumpret, HJ von Richthofen, V Peperzak, L Meyaard
Journal of Experimental Medicine 2021
Recent Progress in the Methodologies to Identify Physiological Ligands of Siglecs
HS Jiang, SC Zhuang, CH Lam, LY Chang, T Angata
Frontiers in immunology 2021
Siglec Signaling in the Tumor Microenvironment
EJ van Houtum, C Büll, LA Cornelissen, GJ Adema
Frontiers in immunology 2021
Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein
M Jarahian, K Marstaller, N Banna, R Ahani, M Etemadzadeh, L Boller, K Azadmanesh, A Cid-Arregui, A Khezri, M Berger, F Momburg, C Watzl
Journal of Innate Immunity 2021
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
Kim N, Lee DH, Choi WS, Yi E, Kim H, Kim JM, Jin HS, Kim HS
BMB Reports 2021
Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment
Berghuis AY, Pijnenborg JF, Boltje TJ, Pijnenborg JM
International Journal of Cancer 2021
Concepts of extracellular matrix remodelling in tumour progression and metastasis
J Winkler, A Abisoye-Ogunniyan, KJ Metcalf, Z Werb
Nature Communications 2020
Harnessing NK Cell Checkpoint-Modulating Immunotherapies
SK Chauhan, U Koehl, S Kloess
Cancers 2020
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
AM Macpherson, SC Barry, C Ricciardelli, MK Oehler
Journal of Clinical Medicine 2020
Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
M Giuliani, A Poggi
Cells 2020
Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness
D Brücher, V Franc, SN Smith, AJ Heck, A Plückthun
mAbs 2020
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
M Cerrano, M Ruella, MA Perales, C Vitale, DG Faraci, L Giaccone, M Coscia, M Maloy, M Sanchez-Escamilla, H Elsabah, A Fadul, E Maffini, G Pittari, B Bruno
Frontiers in immunology 2020
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
S Depil, P Duchateau, SA Grupp, G Mufti, L Poirot
Nature Reviews Drug Discovery 2020
Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases
T Angata
Journal of Biomedical Science 2020
Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype
R Beatson, R Graham, FG Freile, D Cozzetto, S Kannambath, E Pfeifer, N Woodman, J Owen, R Nuamah, U Mandel, S Pinder, C Gillett, T Noll, I Bouybayoune, J Taylor-Papadimitriou, JM Burchell
2020
Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection
K Frank, S Paust
Frontiers in Cellular and Infection Microbiology 2020
Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function
GR Rossi, ES Trindade, F Souza-Fonseca-Guimaraes
Frontiers in immunology 2020
Eosinophil and mast cell Siglecs: From biology to drug target
JA O'Sullivan, AT Chang, BA Youngblood, BS Bochner
Journal of leukocyte biology 2020
Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy
M Bartish, SV del Rincón, CE Rudd, HU Saragovi
Frontiers in immunology 2020
NK Cell-Based Immune Checkpoint Inhibition
M Khan, S Arooj, H Wang
Frontiers in immunology 2020
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways
R Teng, Y Wang, N Lv, D Zhang, RA Williamson, L Lei, P Chen, L Lei, B Wang, J Fu, X Liu, A He, M ODwyer, J Hu
Journal of Immunology Research 2020
Characterization of Surface Receptor Expression and Cytotoxicity of Human NK Cells and NK Cell Subsets in Overweight and Obese Humans
W Naujoks, D Quandt, A Hauffe, H Kielstein, I Bähr, J Spielmann
Frontiers in immunology 2020
Tumor Derived SIGLEC Family Genes May Play Roles in Tumor Genesis, Progression, and Immune Microenvironment Regulation
Z Chen, M Yu, L Guo, B Zhang, S Liu, W Zhang, B Zhou, J Yan, Q Ma, Z Yang, Y Xiao, Y Xu, H Li, Q Ye
Frontiers in Oncology 2020
A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands
E Rodrigues, J Jung, H Park, C Loo, S Soukhtehzari, EN Kitova, F Mozaneh, G Daskhan, EN Schmidt, V Aghanya, S Sarkar, L Streith, CD Laurent, L Nguyen, JP Julien, LJ West, KC Williams, JS Klassen, MS Macauley
Nature Communications 2020
Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design
DM Beckwith, M Cudic
Seminars in Immunology 2020
Targeted glycan degradation potentiates the anticancer immune response in vivo
MA Gray, MA Stanczak, NR Mantuano, H Xiao, JF Pijnenborg, SA Malaker, CL Miller, PA Weidenbacher, JT Tanzo, G Ahn, EC Woods, H Läubli, CR Bertozzi
Nature Chemical Biology 2020
Biological Functions and Analytical Strategies of Sialic Acids in Tumor
X Zhou, G Yang, F Guan
Cells 2020
The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression
Y Zheng, X Ma, D Su, Y Zhang, L Yu, F Jiang, X Zhou, Y Feng, F Ma
Journal of Immunology Research 2020
Reduced Siglec‐7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma
L Tao, S Wang, L Yang, L Jiang, J Li, X Wang
Clinical & Experimental Immunology 2020
Genome-wide DNA methylation and gene expression patterns reflect genetic ancestry and environmental differences across the Indonesian archipelago
HM Natri, KS Bobowik, P Kusuma, CC Darusallam, GS Jacobs, G Hudjashov, JS Lansing, H Sudoyo, NE Banovich, MP Cox, IG Romero, T Lappalainen
PLoS genetics 2020
Sialylation of Human Natural Killer (NK) Cells Is Regulated by IL-2
P Rosenstock, K Bork, C Massa, P Selke, B Seliger, R Horstkorte
Journal of Clinical Medicine 2020
The Emerging Role of the Mammalian Glycocalyx in Functional Membrane Organization and Immune System Regulation
L Möckl
Frontiers in Cell and Developmental Biology 2020
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
NR Mantuano, M Natoli, A Zippelius, H Läubli
Journal for ImmunoTherapy of Cancer 2020
Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis
B Li, B Zhang, X Wang, Z Zeng, Z Huang, L Zhang, F Wei, X Ren, L Yang
OncoImmunology 2020
Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer
S Sivori, MD Chiesa, S Carlomagno, L Quatrini, E Munari, P Vacca, N Tumino, FR Mariotti, MC Mingari, D Pende, L Moretta
Frontiers in immunology 2020
Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress
Y Zhang, P Li, H Fang, G Wang, X Zeng
Frontiers in immunology 2020
Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy
J Lee, JH Sheen, O Lim, Y Lee, J Ryu, D Shin, YY Kim, M Kim
Scientific Reports 2020
Glioblastomas exploit truncated O - linked glycans for local and distant immune modulation via the macrophage galactose-type lectin
SA Dusoswa, J Verhoeff, E Abels, SP Méndez-Huergo, DO Croci, LH Kuijper, E de Miguel, VM Wouters, MG Best, E Rodriguez, LA Cornelissen, SJ van Vliet, P Wesseling, XO Breakefield, DP Noske, T Würdinger, ML Broekman, GA Rabinovich, Y van Kooyk, JJ Garcia-Vallejo
Proceedings of the National Academy of Sciences 2020
DNA methylation‐mediated Siglec‐7 regulation in natural killer cells via two 5′ promoter CpG sites
HT Huang, SC Su, TJ Chiou, YH Lin, YC Shih, YX Wu, TH Fan, YC Twu
Immunology 2020
Siglec-15 as an emerging target for next-generation cancer immunotherapy
Sun J, Lu Q, Sanmanmed MF, Wang J
Clinical cancer research 2020
The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies
P Jandus, KF Boligan, DF Smith, E de Graauw, B Grimbacher, C Jandus, MM Abdelhafez, A Despont, N Bovin, D Simon, R Rieben, HU Simon, RD Cummings, S von Gunten
Blood 2019
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis
H Läubli, L Borsig
Frontiers in immunology 2019
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
A Peixoto, M Relvas-Santos, R Azevedo, LL Santos, JA Ferreira
Frontiers in Oncology 2019
Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance
EG Stamatiades, MO Li
Seminars in Immunology 2019
Harnessing innate immunity in cancer therapy
O Demaria, S Cornen, M Daëron, Y Morel, R Medzhitov, E Vivier
Nature 2019
Glycosylation and its implications in breast cancer
DA Scott, RR Drake
Expert Review of Proteomics 2019
A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease
O Lucar, RK Reeves, S Jost
Frontiers in immunology 2019
Don’t sugarcoat it: How glycocalyx composition influences cancer progression
A Buffone, VM Weaver
The Journal of Cell Biology 2019
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
A Barrow, M Colonna
Cancers 2019
Stage-specific requirement of kinase PDK1 for NK cells development and activation
J He, Y Wang, T Liu, G Liu, S Chen, Q Li, Y Quan, H Yang, J Feng, S Wang, M Yang, Z Dong
Cell Death and Differentiation 2019
Siglec-7 on peripheral blood eosinophils: Surface expression and function
F Legrand, N Landolina, I Zaffran, RO Emeh, E Chen, AD Klion, F Levi-Schaffer
Allergy 2019
Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer
J Daly, M Carlsten, M O'Dwyer
Frontiers in immunology 2019
Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma
KC Santegoets, PR Gielen, C Büll, BM Schulte, ED Kers-Rebel, B Küsters, SA Bossman, M ter Laan, P Wesseling, GJ Adema
Cancer Immunology, Immunotherapy 2019
Targeting Aberrant Sialylation to Treat Cancer
J Munkley, E Scott
Medicines 2019
Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses
H Läubli, A Varki
Cellular and Molecular Life Sciences 2019
Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936
RF Hillary, DL McCartney, SE Harris, AJ Stevenson, A Seeboth, Q Zhang, DC Liewald, KL Evans, CW Ritchie, EM Tucker-Drob, NR Wray, AF McRae, PM Visscher, IJ Deary, RE Marioni
Nature Communications 2019
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A Stanczak, Shoib S Siddiqui, Marcel P Trefny, Daniela S Thommen, Kayluz Frias Boligan, Stephan von Gunten, Alexandar Tzankov, Lothar Tietze, Didier Lardinois, Viola Heinzelmann-Schwarz, Michael S. von Bergwelt-Baildon, Wu Zhang, Heinz-Josef Lenz, Younghan Han, Christopher I. Amos, Mohammedyaseen Syedbasha, Adrian Egli, Frank Stenner, Daniel Speiser, Ajit Varki, Alfred Zippelius, Heinz Läubli
Journal of Clinical Investigation 2018
Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities
E Rodrigues, M Macauley
Cancers 2018
Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
D Stolk, HJ van der Vliet, TD de Gruijl, Y van Kooyk, MA Exley
Frontiers in immunology 2018
Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs
T Angata
Frontiers in immunology 2018
O-linked mucin-type glycosylation in breast cancer
JM Burchell, R Beatson, R Graham, J Taylor-Papadimitriou, V Tajadura-Ortega
Biochemical Society Transactions 2018
A Developed NK-92MI Cell Line with Siglec-7neg Phenotype Exhibits High and Sustainable Cytotoxicity against Leukemia Cells
CH Huang, YJ Liao, TH Fan, TJ Chiou, YH Lin, YC Twu
International journal of molecular sciences 2018
The tumour glyco-code as a novel immune checkpoint for immunotherapy
E RodrÍguez, ST Schetters, Y van Kooyk
Nature Reviews Immunology 2018
Decreased Siglec-9 Expression on Natural Killer Cell Subset Associated With Persistent HBV Replication
D Zhao, X Jiang, Y Xu, H Yang, D Gao, X Li, L Gao, C Ma, X Liang
Frontiers in immunology 2018
A Cartography of Siglecs and Sialyltransferases in Gynecologic Malignancies: Is There a Road Towards a Sweet Future?
Q Haas, C Simillion, S von Gunten
Frontiers in Oncology 2018
Functional Inhibitory Siglec-6 Is Upregulated in Human Colorectal Cancer-Associated Mast Cells
Y Yu, BR Blokhuis, MA Diks, A Keshavarzian, J Garssen, FA Redegeld
Frontiers in immunology 2018
Siglec-7 engagement by GBS β-protein suppresses pyroptotic cell death of natural killer cells
JJ Fong, CM Tsai, S Saha, V Nizet, A Varki, JD Bui
Proceedings of the National Academy of Sciences 2018
Sialylation is involved in cell fate decision during development, reprogramming and cancer progression
F Li, J Ding
Protein & Cell 2018
Sialic acids as cellular markers of immunomodulatory action of dexamethasone on glioma cells of different immunogenicity
P Wielgat, E Trofimiuk, R Czarnomysy, JJ Braszko, H Car
Molecular and Cellular Biochemistry 2018
Tailoring Natural Killer cell immunotherapy to the tumour microenvironment
AD Barrow, M Colonna
Seminars in Immunology 2017
IVIG regulates the survival of human but not mouse neutrophils
C Schneider, S Wicki, S Graeter, TM Timcheva, CW Keller, I Quast, D Leontyev, IK Djoumerska-Alexieva, F Käsermann, SM Jakob, PA Dimitrova, DR Branch, RD Cummings, JD Lünemann, T Kaufmann, HU Simon, S Gunten
Scientific Reports 2017
Natural Killer Cells - Their Role in Tumour Immunosurveillance
P Sharma
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH 2017
Viewing Siglecs through the lens of tumor immunology
I Fraschilla, S Pillai
Immunological Reviews 2017
Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans
P Rosenstock, R Horstkorte, VS Gnanapragassam, J Harth, H Kielstein
Immunologic Research 2017
Influence of Irradiated Peripheral Blood Mononuclear Cells on Both Ex Vivo Proliferation of Human Natural Killer Cells and Change in Cellular Property
M Delso-Vallejo, J Kollet, U Koehl, V Huppert
Frontiers in immunology 2017
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
M Ruella, SS Kenderian
BioDrugs 2017
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors
H Torikai, LJ Cooper
Molecular Therapy 2016
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer
AJ Cagnoni, JM Sáez, GA Rabinovich, KV Mariño
Frontiers in Oncology 2016
Antibody repertoire profiling with mimotope arrays
S Pashova, C Schneider, S Gunten, A Pashov
Human Vaccines & Immunotherapeutics 2016
Targeting Selectins and Their Ligands in Cancer
A Natoni, MS Macauley, ME ODwyer
Frontiers in Oncology 2016
Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer
S Mereiter, M Balmaña, J Gomes, A Magalhães, CA Reis
Frontiers in Oncology 2016
Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer
G Greville, A McCann, PM Rudd, R Saldova
Epigenetics : official journal of the DNA Methylation Society 2016
A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer
L Cornelissen, SV Vliet
Biomolecules 2016
Modulation of innate immunity in the tumor microenvironment
E Gonzalez-Gugel, M Saxena, N Bhardwaj
Cancer Immunology, Immunotherapy 2016
Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents
JL Daniotti, RD Lardone, AA Vilcaes
Frontiers in Oncology 2016
The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression
AF Nardy, L Freire-de-Lima, CG Freire-de-Lima, A Morrot
Frontiers in Oncology 2016
Immunoreceptors on neutrophils
DJ van Rees, K Szilagyi, TW Kuijpers, HL Matlung, TK van Berg
Seminars in Immunology 2016
The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9
R Beatson, V Tajadura-Ortega, D Achkova, G Picco, TD Tsourouktsoglou, S Klausing, M Hillier, J Maher, T Noll, PR Crocker, J Taylor-Papadimitriou, JM Burchell
Nature Immunology 2016
Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury
AS Allegretti, G Ortiz, S Kalim, J Wibecan, D Zhang, HY Shan, D Xu, RT Chung, SA Karumanchi, RI Thadhani
Digestive Diseases and Sciences 2016
Precision glycocalyx editing as a strategy for cancer immunotherapy
H Xiao, EC Woods, P Vukojicic, CR Bertozzi
Proceedings of the National Academy of Sciences 2016
Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression:
RP Schleimer, RL Schnaar, BS Bochner
Current Opinion in Allergy and Clinical Immunology 2016
Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis
S Cascio, O Finn
Biomolecules 2016
SAMP-ening down sepsis
A Coady, V Nizet
Annals of translational medicine 2016
Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells
Perdicchio M, Cornelissen LA, Streng-Ouwehand I, Engels S, Verstege MI, Boon L, Geerts D, van Kooyk Y, Unger WW
Oncotarget 2016
A Clinical and Laboratory Approach to the Evaluation of Innate Immunity in Pediatric CVID Patients
N Kutukculer, E Azarsiz, NE Karaca, E Ulusoy, G Koturoglu, G Aksu
Frontiers in immunology 2015
Siglec receptors impact mammalian lifespan by modulating oxidative stress: Numbers of CD33rSiglecs ( A ), KLK ( B ), IgG Fc receptors ( C ), and TLRs genes ( D ) and maximum lifespan in 14 mammalian species listed in Figure 1—figure supplement 1. ( E and F ) Correlation of CD33rSIGLEC s and maximum lifespan after correction for average adult body weight and phylogeny. PGLS: λ = 1, phylogenetic tree I ( E ) or tree II ( F ) were used. The Pearson's correlation coefficient (R 2 ) for each plot is indicated
F Schwarz, OM Pearce, X Wang, AN Samraj, H Läubli, JO Garcia, H Lin, X Fu, A Garcia-Bingman, P Secrest, CE Romanoski, C Heyser, CK Glass, SL Hazen, N Varki, A Varki, P Gagneux
eLife 2015
Combination cancer immunotherapy and new immunomodulatory targets
KM Mahoney, PD Rennert, GJ Freeman
Nature Reviews Drug Discovery 2015
Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation
BS Bochner, N Zimmermann
Journal of Allergy and Clinical Immunology 2015
Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches
T Angata, CM Nycholat, MS Macauley
Trends in Pharmacological Sciences 2015
The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites
C Schneider, DF Smith, RD Cummings, KF Boligan, RG Hamilton, BS Bochner, S Miescher, HU Simon, A Pashov, T Vassilev, S Gunten
Science Translational Medicine 2015
Chemical Lectinology: Tools for Probing the Ligands and Dynamics of Mammalian Lectins In Vivo
B Belardi, CR Bertozzi
Chemistry & Biology 2015
Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer
H Laubli, OM Pearce, F Schwarz, SS Siddiqui, L Deng, MA Stanczak, L Deng, A Verhagen, P Secrest, C Lusk, AG Schwartz, NM Varki, JD Bui, A Varki
Proceedings of the National Academy of Sciences 2014
Siglec-mediated regulation of immune cell function in disease
MS Macauley, PR Crocker, JC Paulson
Nature Reviews Immunology 2014
Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense
KF Boligan, C Mesa, LE Fernandez, S Gunten
Cellular and Molecular Life Sciences 2014
Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations
S Gunten
Clinical & Experimental Immunology 2014
Lectin Galactoside-binding Soluble 3 Binding Protein (LGALS3BP) Is a Tumor-associated Immunomodulatory Ligand for CD33-related Siglecs
H Laubli, F Alisson-Silva, MA Stanczak, SS Siddiqui, L Deng, A Verhagen, N Varki, A Varki
The Journal of biological chemistry 2014
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 … 9 10 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 2 news outlets
Posted by 2 X users
Referenced in 27 patents
307 readers on Mendeley
See more details